“OncoRACT” – The First Therapy Specific RACT for Clinical Trials

Many risks in clinical trials are therapy specific. Because of that, the currently available tools addressing those risks, like the TransCelerate Risk Assessment and Categorization Tools (RACTs), are now becoming therapy specific as well. The first therapy focused risk library Oncology RACT (OncoRACT) recently got available.

The OncoRACT library has emerged in response to the large number of challenges that today’s Oncology trials face. Specific subject safety risks, adjudication risks, therapy cycle risks, Oncology-specific outcomes and subject recruitment risks are explicitly addressed by OncoRACT.

Read more at ACT, publication: “Oncology therapy focused RACT emerges” by Moe Alsumidaie

By Linda Bunschoten - Chief Marketing Officer|2020-09-23T10:54:27+02:00May 1, 2018|Neat Features, News, RBQM Product Updates|Comments Off

About the Author: Linda Bunschoten - Chief Marketing Officer

Linda has 25+ years of experience uncovering pain points and strategizing with companies in the healthcare industry in order to secure and retain more clients. Her chief thinking responsibilities include translating insight into strategy and ensure that all MarCom and Product Management activities contribute to our overall customer experience and meet our industry’s quality expectations.